Trial date set for Teva's generic COPAXONE patent infringement litigation against Momenta

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced that the United States District Court for the Southern District of New York has set a trial date of September 7, 2011 in the Company's ongoing patent infringement litigation against Momenta Pharmaceuticals, Inc./Sandoz Inc. and Mylan Pharmaceuticals, Inc./Mylan Inc./Natco Pharma Ltd. regarding their purported generic versions of COPAXONE® (glatiramer acetate injection).

"We are very pleased to have a trial date as we are confident we will prevail in this litigation," said Richard Egosi, Teva's Chief Legal Officer. "Teva remains committed to vigorously defending its intellectual property rights against infringement."

Source:

Teva Pharmaceutical Industries Ltd.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
People taking immunosuppressant produce weaker, shorter-lived antibodies after COVID-19 vaccination